Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

F. Zappa; C. Droege; D. Betticher; R. von Moos; L. Bubendorf; A. Ochsenbein; O. Gautschi; E. Oppliger Leibundgut; P. Froesch; R. Stahel; T. Hess; D. Rauch; P. Schmid; M. Mayer; S. Crowe; P. Brauchli; K. Ribi; M. Pless

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

F. Zappa, C. Droege, D. Betticher, R. von Moos, L. Bubendorf, A. Ochsenbein, O. Gautschi, E. Oppliger Leibundgut, P. Froesch, R. Stahel, T. Hess, D. Rauch, P. Schmid, M. Mayer, S. Crowe, P. Brauchli, K. Ribi, M. Pless

Careum Hochschule Gesundheit

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	239-244
Seitenumfang	6
Fachzeitschrift	Lung Cancer
Jahrgang	78
Ausgabenummer	3
Publikationsstatus	Veröffentlicht - 2012

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dieses zitieren

Zappa, F., Droege, C., Betticher, D., von Moos, R., Bubendorf, L., Ochsenbein, A., Gautschi, O., Oppliger Leibundgut, E., Froesch, P., Stahel, R., Hess, T., Rauch, D., Schmid, P., Mayer, M., Crowe, S., Brauchli, P., Ribi, K., & Pless, M. (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3), 239-244.

@article{ef369f21c3324858bc649713e51be5bf,

title = "Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)",

author = "F. Zappa and C. Droege and D. Betticher and {von Moos}, R. and L. Bubendorf and A. Ochsenbein and O. Gautschi and {Oppliger Leibundgut}, E. and P. Froesch and R. Stahel and T. Hess and D. Rauch and P. Schmid and M. Mayer and S. Crowe and P. Brauchli and K. Ribi and M. Pless",

year = "2012",

language = "English",

volume = "78",

pages = "239--244",

journal = "Lung Cancer",

number = "3",

}

Zappa, F, Droege, C, Betticher, D, von Moos, R, Bubendorf, L, Ochsenbein, A, Gautschi, O, Oppliger Leibundgut, E, Froesch, P, Stahel, R, Hess, T, Rauch, D, Schmid, P, Mayer, M, Crowe, S, Brauchli, P, Ribi, K & Pless, M 2012, 'Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)', Lung Cancer, Jg. 78, Nr. 3, S. 239-244.

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). / Zappa, F.; Droege, C.; Betticher, D. et al.
in: Lung Cancer, Jahrgang 78, Nr. 3, 2012, S. 239-244.

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

TY - JOUR

T1 - Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

AU - Zappa, F.

AU - Droege, C.

AU - Betticher, D.

AU - von Moos, R.

AU - Bubendorf, L.

AU - Ochsenbein, A.

AU - Gautschi, O.

AU - Oppliger Leibundgut, E.

AU - Froesch, P.

AU - Stahel, R.

AU - Hess, T.

AU - Rauch, D.

AU - Schmid, P.

AU - Mayer, M.

AU - Crowe, S.

AU - Brauchli, P.

AU - Ribi, K.

AU - Pless, M.

PY - 2012

Y1 - 2012

M3 - Article

VL - 78

SP - 239

EP - 244

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -